Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT versus PROTONIX IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT versus PROTONIX IV.
DEXILANT vs PROTONIX IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
30 mg orally once daily for up to 8 weeks; for healing esophagitis, 60 mg orally once daily for up to 8 weeks; maintenance 30 mg orally once daily.
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours in healthy subjects, but due to prolonged gastric acid suppression via irreversible binding to proton pumps, duration of action exceeds 24 hours. Half-life is not directly correlated with pharmacodynamic effect.
1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment.
Renal (approximately 50% as inactive metabolites) and fecal (approximately 50% as inactive metabolites).
Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor